Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

sitaxentan sodium

THELIN

sitaxentan sodium (THELIN) is a endothelin receptor, et-a/et-b antagonist.

EMA: withdrawn Cardiovascular system (C02) C02KX03
Patents linked 20
Pipeline programs 4
News articles 0
Drug details — sitaxentan sodium
Class
Cardiovascular system (C02)
Route
—
Patents
20
Programs
4
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

sitaxentan sodium (THELIN) is a endothelin receptor, et-a/et-b antagonist.

Key facts

INN sitaxentan sodium
Brand THELIN
Mechanism Endothelin receptor, ET-A/ET-B antagonist
Target Endothelin receptor, ET-A/ET-B
Therapeutic class Cardiovascular system (C02)
ATC code C02KX03

Mechanism of action

Endothelin receptor, ET-A/ET-B antagonist

Primary target: Endothelin receptor, ET-A/ET-B

Approval history

Authority Status Date
EMA withdrawn —

Pipeline programs

Search pipeline
  1. 67896062PAH1011 Phase 1 · Anaxis Pharma · Pulmonary Arterial Hypertension
  2. A Clinical Study to Compare the Impact of Mul... Phase 1 · Anaxis Pharma · Pulmonary Arterial Hypertension
  3. A Phase 1 Study of JNJ-79032421 Targeting Mes... for Advanced Stage Solid Tumors Phase 1 · Janssen-Cilag International N.V · Advanced Stage Solid Tumors
  4. CT-95 Phase 1 · Context Therapeutics · Mesothelin-Expressing Tumors

Related & competitor drugs

Browse all drugs
  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. dofetilide Cardiovascular system (C01)

Related patents

Browse patents

  1. US 12180296

    Cross species single domain antibodies targeting mesothelin for treating solid tumors

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11986517

    Cancer vaccines targeting mesothelin and uses thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11932698

    Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11795215

    Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11390683

    Anti-mesothelin polypeptides and proteins

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11154602

    Cancer vaccines targeting mesothelin and uses thereof

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10683362

    Recombinant immunotoxin targeting mesothelin

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10258606

    Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9803022

    Mesothelin domain-specific monoclonal antibodies and use thereof

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9751932

    Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9416190

    Mesothelin antibodies and methods for eliciting potent antitumor activity

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9409992

    Mesothelin domain-specific monoclonal antibodies and use thereof

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9359447

    Anti-mesothelin chimeric antigen receptors

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9062347

    Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8999934

    Treatment of astrocytes-tumor cells inhibitors of endothelin receptors

    Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8623828

    Blocking mesothelin peptide fragments

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8460660

    Anti-mesothelin antibodies

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8357783

    Human anti-mesothelin monoclonal antibodies

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7709252

    Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is sitaxentan sodium?

sitaxentan sodium (THELIN) is a endothelin receptor, et-a/et-b antagonist.

What is the brand name for sitaxentan sodium?

THELIN is a marketed brand name for sitaxentan sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.